Herbert Smith Freehills advises Zydus Lifesciences Limited on acquisition of the UK based LiqMeds Group

Leading international law firm Herbert Smith Freehills has advised Zydus Pharmaceuticals UK Limited, a 100% subsidiary of Indian multinational pharmaceutical company Zydus Lifesciences Limited on its agreement to acquire UK headquartered LiqMeds group of companies which has capabilities and specialisation in development, manufacturing, and supply of oral liquid products for global markets, which it currently commercializes through partners.

Zydus Pharmaceuticals UK Limited will pay an upfront consideration of £68m (subject to customary adjustments) and yearly earn-outs until 2026 depending on achievement of certain agreed milestones.

Zydus Lifesciences Limited is an innovative, global lifesciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. Over the last decade, Zydus has introduced several innovative, first-in-class products in the market for treating unmet healthcare needs with vaccines, therapeutics, biologicals and biosimilars.

The Herbert Smith Freehills team was led by Corporate partner Alan Montgomery along with Corporate partner Siddhartha Shukla. They were supported by Corporate of counsel Martyn Jones and associates Meera Thakrar, Adya Garg and Savannah Van Dongen, and IP associate Kate Peck.

The transaction demonstrates the firm's ability to combine its deep pharmaceutical sector knowledge and strong M&A expertise to deliver the best solutions that meet clients' needs.